WEDNESDAY, May 26, 2004 (HealthDayNews) -- Millions of women who have suffered through yeast infections might welcome this news: Another treatment for the common condition is on the horizon.
Positive trial results for the peptide molecule CZEN-002 for treatment of vaginal yeast infection were announced this week by Zengen Inc.
The open label, non-randomized study of 20 women with yeast infections (17 completed the study) evaluated the safety, tolerability and pharmacokinetics of CZEN-002. The study found that five days of treatment provided evidence of its efficacy.
The trial results also indicated that CZEN-002 is safe and well-tolerated, with no severe adverse reactions among the study volunteers.
"This trial clearly established the efficacy of CZEN-002," lead investigator Dr. William Smith, an associate professor of clinical medicine at Tulane University School of Medicine and Louisiana State University Medical Center, said in a prepared statement.
"The encouraging results provide hope that this compound may become a new treatment option for the millions of women diagnosed each year" with yeast infections, Smith said.
More information
The U.S. National Library of Medicine has more about vaginal yeast infection.
